Nevro Corp. (NYSE:NVRO) Receives Consensus Rating of “Buy” from Analysts
Nevro Corp. (NYSE:NVRO) has been assigned a consensus recommendation of “Buy” from the thirteen ratings firms that are presently covering the firm. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $70.67.
NVRO has been the subject of several analyst reports. B. Riley reissued a “buy” rating on shares of Nevro Corp. in a report on Friday, September 16th. Wells Fargo & Co. initiated coverage on shares of Nevro Corp. in a report on Tuesday, July 12th. They set an “outperform” rating for the company. Piper Jaffray Cos. initiated coverage on shares of Nevro Corp. in a report on Friday, July 22nd. They set an “overweight” rating for the company. William Blair reissued an “outperform” rating on shares of Nevro Corp. in a report on Monday, July 18th. Finally, Bank of America Corp. initiated coverage on shares of Nevro Corp. in a report on Monday, August 8th. They set a “buy” rating for the company.
A number of large investors have recently modified their holdings of NVRO. Royal Bank of Canada increased its stake in shares of Nevro Corp. by 1,246,130.0% in the first quarter. Royal Bank of Canada now owns 249,246 shares of the company’s stock worth $14,022,000 after buying an additional 249,226 shares during the last quarter. Seven Eight Capital LLC acquired a new stake in shares of Nevro Corp. during the first quarter worth $214,000. Cormorant Asset Management LLC increased its stake in shares of Nevro Corp. by 82.9% in the first quarter. Cormorant Asset Management LLC now owns 485,386 shares of the company’s stock worth $27,308,000 after buying an additional 220,000 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Nevro Corp. during the first quarter worth $380,000. Finally, Bellevue Group AG acquired a new stake in shares of Nevro Corp. during the first quarter worth $422,000.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/nevro-corp-nysenvro-receives-consensus-rating-of-buy-from-analysts.html
Nevro Corp. (NYSE:NVRO) traded down 2.430% during trading on Friday, reaching $93.745. 342,650 shares of the company’s stock traded hands. Nevro Corp. has a 12 month low of $36.51 and a 12 month high of $106.93. The company has a 50-day moving average of $97.76 and a 200 day moving average of $78.28. The stock’s market capitalization is $2.67 billion.
Nevro Corp. Company Profile
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.
Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.